Apellis Pharmaceuticals IncのFCF yieldは-7.52%です。
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.